These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 12926801)

  • 1. Lupus anticoagulant in patients with chronic venous insufficiency.
    Fink AM; Kottas-Heldenberg A; Bayer PM; Bednar R; Steiner A
    Acta Derm Venereol; 2003; 83(4):287-9. PubMed ID: 12926801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lupus anticoagulant and venous leg ulceration.
    Fink AM; Kottas-Heldenberg A; Mayer W; Partsch H; Bayer PM; Bednar R; Steiner A
    Br J Dermatol; 2002 Feb; 146(2):308-10. PubMed ID: 11903245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The activated seven lupus anticoagulant assay detects clinically significant antibodies.
    Moore GW; Rangarajan S; Savidge GF
    Clin Appl Thromb Hemost; 2008 Jul; 14(3):332-7. PubMed ID: 17895508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dilute Russell's viper venom and activated partial thromboplastin time in lupus anticoagulant diagnosis: is mixing essential?
    Chandrashekar V
    Blood Coagul Fibrinolysis; 2016 Jun; 27(4):408-11. PubMed ID: 26626041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of Platelin LS and dilute Russell's viper venom for the screening of lupus anticoagulant in patients with venous thromboembolism.
    Morelli VM; Rodrigues CA; Noguti MA; Matos MF; da Silveira RC; Ribeiro AA; Lourenço DM
    Blood Coagul Fibrinolysis; 2007 Jul; 18(5):401-5. PubMed ID: 17581313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lupus anticoagulant and the skin. A longterm follow-up study of SLE patients with special reference to histopathological findings.
    Stephansson EA; Niemi KM; Jouhikainen T; Vaarala O; Palosuo T
    Acta Derm Venereol; 1991; 71(5):416-22. PubMed ID: 1684471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Detection of lupus anticoagulant using a modified diluted Russell's viper venom time test].
    Sato K; Kagami K; Asai M; Nakashima N; Takamatsu J
    Rinsho Byori; 1995 Mar; 43(3):263-8. PubMed ID: 7745832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of the mixing test in laboratory diagnoses of lupus anticoagulant: the fate of the mixing test in integrated lupus anticoagulant test systems.
    Hong SK; Hwang SM; Kim JE; Kim HK
    Blood Coagul Fibrinolysis; 2012 Dec; 23(8):739-44. PubMed ID: 22964767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newly developed dilute Russell's viper venom reagents for lupus anticoagulant detection with improved specificity.
    Moore GW; Peyrafitte M; Dunois C; Amiral J
    Lupus; 2018 Jan; 27(1):95-104. PubMed ID: 28549386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyoderma-gangraenosum-like ulcers associated with lupus anticoagulant.
    Selva A; Ordi J; Roca M; Huguet P; Castells-Rodellas A; Vilardell M
    Dermatology; 1994; 189(2):182-4. PubMed ID: 8075451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical syndromes associated with lupus anticoagulants.
    Kampe CE
    Semin Thromb Hemost; 1994; 20(1):16-26. PubMed ID: 8059230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lupus anticoagulants and thrombosis: clinical association of different coagulation and immunologic tests.
    Galli M; Dlott J; Norbis F; Ruggeri L; Cler L; Triplett DA; Barbui T
    Thromb Haemost; 2000 Dec; 84(6):1012-6. PubMed ID: 11154107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. False-positive lupus anticoagulant in patients receiving rivaroxaban: 24 h since the last dose are needed to exclude antiphospholipid syndrome.
    Góralczyk T; Iwaniec T; Wypasek E; Undas A
    Blood Coagul Fibrinolysis; 2015 Jun; 26(4):473-5. PubMed ID: 25402189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity of lupus anticoagulant (LA) antibodies: LA activity in dilute Russell's Viper Venom Time and dilute Kaolin Clotting Time detect different populations of antibodies in patients with the "antiphospholipid" syndrome.
    Kandiah DA; Krilis SA
    Thromb Haemost; 1998 Aug; 80(2):250-7. PubMed ID: 9716148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus.
    Somers E; Magder LS; Petri M
    J Rheumatol; 2002 Dec; 29(12):2531-6. PubMed ID: 12465147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Leg ulcers and antiphospholipid antibodies. Prospective study of 48 cases].
    Alcaraz I; Lefevre I; Wiart T; Lafon C; Forzy G; Modiano P
    Ann Dermatol Venereol; 1999 Apr; 126(4):313-6. PubMed ID: 10421932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical importance of positive test results for lupus anticoagulant and anticardiolipin antibodies.
    Proven A; Bartlett RP; Moder KG; Chang-Miller A; Cardel LK; Heit JA; Homburger HA; Petterson TM; Christianson TJ; Nichols WL
    Mayo Clin Proc; 2004 Apr; 79(4):467-75. PubMed ID: 15065611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A colour Doppler ultrasound study of venous reflux in patients with chronic leg ulcers.
    Magnusson MB; Nelzén O; Risberg B; Sivertsson R
    Eur J Vasc Endovasc Surg; 2001 Apr; 21(4):353-60. PubMed ID: 11359338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombophilia in venous leg ulcers: a comparative study in early and later onset.
    Calistru AM; Baudrier T; Gonçalves L; Azevedo F
    Indian J Dermatol Venereol Leprol; 2012; 78(3):406. PubMed ID: 22565455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort.
    Petri M
    Thromb Res; 2004; 114(5-6):593-5. PubMed ID: 15507296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.